News

Published on 21 Mar 2023 on Benzinga via Yahoo Finance

Moderna Wants To Charge About $130 Per COVID-19 Vaccine Dose


Article preview image

From now on, Moderna Inc (NASDAQ: MRNA) expects to charge $130 per dose for its COVID-19 vaccine as purchases move from the government to the private sector."There are different customers negotiating different prices right now, which is why it's a little bit complicated," the company's president Stephen Hoge said in an interview ahead of a Congressional hearing run by Democratic U.S. Senator Bernie Sanders on Moderna's pricing plans.Moderna previously considered pricing its COVID vaccine in a range of $110 to $130 per dose in the U.S., similar to Pfizer Inc (NYSE: PFE) / BioNTech SE's (NASDAQ: BNTX) shot.Hoge said the government's Medicare health plan for seniors pays $70 per dose for the seasonal influenza vaccine. Hoge said that there were two to three times more hospitalizations and deaths from COVID in the past three months alone than from the flu. That went into the company's pricing reasoning.The Biden Administration has said the pandemic public health emergency will end in May, shifting price negotiations to insurers and other purchasers instead of just the federal government, Reuters reported.In January, Senator Bernie Sanders had written to Moderna CEO Stéphane Bancel to refrain from shooting up the prices of the COVID-19 vaccine because of the government funding it received.Bancel is expected to testify this month on its plans to raise the price of its COVID-19 vaccine in front of the Senate.Price Action: MRNA shares are up 0.31% at $155 during the premarket session on the last check Tuesday.Photo via Wikimedia Commons

NASDAQ.BNTX price evolution
NASDAQ.MRNA price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
BioNTech stock target cut to $91 from $100 by Goldman Sachs By Investing.com

BioNTech stock target cut to $91 from $100 by Goldman Sachs

Investing.com 21 Mar 2024

BioNTech Touts Its Oncology Shift After Reporting Disappointing Fourth Quarter Financials

BioNTech SE (NASDAQ: BNTX) is way past its glorious Covid-19 days, when it thrived with Pfizer In...

Benzinga via Yahoo Finance 20 Mar 2024

BioNTech Se (BNTX) Q4 2023 Earnings Call Transcript

Image source: The Motley Fool. BioNTech Se (NASDAQ: BNTX)Q4 2023 Earnings CallMar 20, 2024, 8:00 ...

Motley Fool via Yahoo Finance 20 Mar 2024

Why Moderna Shares Are Falling - Moderna (NASDAQ:MRNA)

Moderna Inc MRNA shares are trading lower by 2.7% to $102.25 during Wednesday’s session in possib...

Benzinga 20 Mar 2024

Why Is BioNTech Stock Trading Lower On Wednesday? - BioNTech (NASDAQ:BNTX)

Pfizer Inc’s PFE German partner, BioNTech SE BNTX, reported fourth-quarter 2023 EPS of fiscal yea...

Benzinga 20 Mar 2024

BioNTech stock slips after Q4 results (NASDAQ:BNTX)

BioNTech (BNTX) reports Q4 financials, with a ~65% drop in revenue due to declining demand for CO...

Seeking Alpha 20 Mar 2024

BioNTech Q4 earnings: COVID franchise to drive cash in 2024

BioNTech reported its financial results for the fourth quarter today. Here's what its CEO Ugur Sa...

Invezz 20 Mar 2024

BioNTech names new chief commercial officer ahead of launches

BioNTech names new chief commercial officer ahead of launches

Investing.com 20 Mar 2024

BioNTech SE (NASDAQ:BNTX) Q4 2023 Earnings Call Transcript

BioNTech SE (NASDAQ:BNTX) Q4 2023 Earnings Call Transcript March 20, 2024 BioNTech SE misses on e...

Insider Monkey via Yahoo Finance 20 Mar 2024

Will Weakness in BioNTech SE's (NASDAQ:BNTX) Stock Prove Temporary Given Strong Fundamentals?

With its stock down 7.5% over the past three months, it is easy to disregard BioNTech (NASDAQ:BNT...

Simply Wall St. via Yahoo Finance 12 Mar 2024